Download WGU D345 Pre- Assessment (Latest 2026/ 2027 Update) Psychopharmacology Q&A | 100% Correct and more Assignments Pharmacology in PDF only on Docsity!
WGU D345 Pre- Assessment (Latest 2026/
2027 Update) Psychopharmacology for
Advanced Psychiatric Mental Health
Practice| 100% Verified Questions & Answers
| Grade A
Q: A combat veteran presents with anxiety, flashbacks, distressing dreams, irritable mood,
and sleep disturbance. The patient's capacity for enjoyment is limited and the patient avoids people and places that trigger memories of combat due to anxiety and feeling uncomfortable. Which medication should be used to treat this patient? a. Olanzapine (Zyprexa) b. Selegiline (Emsam) c. Quetiapine (Seroquel) d. Sertraline (Zoloft) ANS: D Sertraline (Zoloft) is the appropriate medication for this patient, who presents with symptoms consistent with post-traumatic stress disorder (PTSD). Selective serotonin reuptake inhibitors (SSRIs) such as sertraline are first-line pharmacologic treatments for PTSD due to their efficacy in reducing anxiety, intrusive thoughts, and hyperarousal symptoms. Atypical antipsychotics like olanzapine and quetiapine may be used as adjunctive treatments but are not first-line. Selegiline is a monoamine oxidase inhibitor (MAOI) primarily used for Parkinson's disease and depression, not PTSD. Thus, sertraline is the best option for treating PTSD symptoms in this combat veteran.
Q: A nurse practitioner (NP) completes an assessment for the presence of abnormal
involuntary movements on a patient who has been taking various psychotropic medications for the past several years. The NP diagnoses the patient with tardive dyskinesia (TD).Which medication should be prescribed to treat the patient? a. Duloxetine (Cymbalta) b. Phenelzine (Nardil) c. Propranolol (Inderal) d. Deutetrabenazine (Austedo) ANS: D Deutetrabenazine (Austedo) is the appropriate medication for treating tardive dyskinesia (TD). TD is a movement disorder characterized by repetitive, involuntary movements, often caused by long-term use of dopamine-blocking agents such as antipsychotics. Deutetrabenazine is a vesicular monoamine transporter 2 (VMAT2) inhibitor, which helps reduce dopamine release and mitigate abnormal involuntary movements. Duloxetine is a serotonin-norepinephrine reuptake inhibitor (SNRI) used for depression and chronic pain conditions. Phenelzine is a monoamine oxidase inhibitor (MAOI) used for treatment-resistant depression, not TD. Propranolol is a beta-blocker used primarily for essential tremors and akathisia but is not effective for TD. Thus, deutetrabenazine is the best choice for treating TD in this patient.
Q: A patient with a history of social anxiety and no previous medication history recently
started college. Upon moving into the dormitories, the patient immediately experienced heightened anxiety and reported low moods. Which medication should be used to address these symptoms? a. Olanzapine (Zyprexa) b. Risperidone (Risperdal) c. Paroxetine (Paxil) d. Aripiprazole (Abilify)
Q: A school-age child diagnosed with separation anxiety disorder and treated with
psychotherapy continues to exhibit symptoms. The child has not been able to attend kindergarten. Which medication should be used to treat this disorder? a. Citalopram (Celexa) b. Clonidine (Catapres) c. Aripiprazole (Abilify) d. Amitriptyline (Elavil) ANS: A Citalopram (Celexa) is the appropriate medication for this child, who presents with separation anxiety disorder (SAD) that has not responded to psychotherapy alone. Selective serotonin reuptake inhibitors (SSRIs), such as citalopram, are the first-line pharmacologic treatment for pediatric anxiety disorders, including separation anxiety. SSRIs help reduce excessive fear, distress, and avoidance behaviors, enabling the child to better cope with being apart from caregivers. Clonidine is an alpha-2 adrenergic agonist primarily used for ADHD-related hyperactivity and impulsivity, not separation anxiety. Aripiprazole is an atypical antipsychotic used for conditions like autism-related irritability, bipolar disorder, and schizophrenia, not first-line for anxiety disorders. Amitriptyline is a tricyclic antidepressant (TCA) that is not commonly used in children due to its side effect profile and risk of toxicity. Thus, citalopram is the best choice for treating separation anxiety disorder in this child.
Q: A nurse practitioner (NP) has a patient who is taking lamotrigine (Lamictal) for bipolar
maintenance. The patient is well maintained on the medication. The patient expresses a desire to start oral contraceptives. Which psychoeducation should the NP provide to the patient in response to this request? a. It is okay for the patient to start the oral contraceptive if the patient remains in contact with the NP. b. Some oral contraceptives may increase lamotrigine levels, so the dosage may need to be decreased.
c. Lamotrigine is contraindicated, so it needs to be cross-titrated to another mood stabilizer. d. Some oral contraceptives may decrease lamotrigine levels, so the dose may need to be increased. ANS: D Some oral contraceptives may decrease lamotrigine levels, so the dose may need to be increased. Estrogen-containing oral contraceptives can induce the metabolism of lamotrigine by increasing the activity of glucuronidation, leading to reduced lamotrigine plasma concentrations and potentially decreased efficacy in mood stabilization. This interaction may necessitate a dose adjustment of lamotrigine to maintain therapeutic levels. Lamotrigine is not contraindicated with oral contraceptives, so cross-titration to another mood stabilizer is not necessary. Additionally, the interaction between lamotrigine and oral contraceptives is well-documented, meaning proactive monitoring and dose adjustments are preferred over merely maintaining contact without changes. Thus, the best psychoeducation for the patient is that some oral contraceptives may decrease lamotrigine levels, requiring a dosage increase.
Q: A nurse practitioner (NP) is managing a patient who has generalized anxiety disorder.
Upon initial assessment, the Generalized Anxiety Disorder-7 (GAD-7) was 19. The patient was initiated on escitalopram (Lexapro) eight weeks ago and is currently taking 10 mg daily. During today's visit, the patient's GAD-7 is 15. The NP evaluates the pharmacological outcome by using standardized symptom measurements. What should the NP determine as this patient's current status and plan of treatment? a. The patient is asymptomatic, so increasing the dose is warranted. b. The patient is symptomatic, so increasing the dose is warranted. c. The patient is asymptomatic, so no change in medication is necessary. d. The patient is symptomatic, though no change in medication is necessary. ANS: B The patient is still symptomatic, so increasing the dose is warranted. The GAD-7 score has decreased from 19 to 15, indicating some improvement, but the patient still falls within the moderate to severe range of anxiety symptoms. Since the patient has been on escitalopram (Lexapro) 10 mg daily for eight weeks, an adequate trial has occurred, and further dose optimization is appropriate. The typical therapeutic dose range for escitalopram in generalized anxiety disorder (GAD) is 10- 20 mg daily, meaning a dose increase to 15 or 20 mg could enhance symptom relief. Simply
Q: A high school graduate took a gap year to work with a therapist on reducing ADHD
symptoms. While making significant progress, they still struggle with note-taking in science classes for their chemistry major. Diagnosed with ADHD at age six, they were previously on amphetamine (Adzenys ER) and now take the maximum dose of methylphenidate (Cotempla XR-ODT) and clonidine (Catapres) twice daily. The treatment team agrees therapy and medication have provided maximum benefit. The student has also engaged in ADHD coaching, but note-taking difficulties persist, affecting academic performance. Which action should the NP take? a. Advise the school about the diagnosis and obtain legal counsel for accommodations b. Suggest changing to an easier major and adjust medication dosages c. Suggest changing to an easier major and continue current medications d. Advise the school about the diagnosis and complete forms for accommodations ANS: D The most appropriate action is to advise the school about the diagnosis and treatment plan and complete the forms requesting accommodations. The patient has a well-established diagnosis of ADHD, has undergone comprehensive treatment with therapy, ADHD coaching, and medication at maximum benefit, yet still struggles with note-taking, which is affecting academic performance. Under the Americans with Disabilities Act (ADA) and Section 504 of the Rehabilitation Act, students with ADHD are eligible for accommodations to support their learning needs. Accommodations may include note-taking assistance, extended test-taking time, quiet testing environments, or the use of assistive technology. Changing majors is not necessary when the student has a legitimate need for support that can help them succeed in their chosen field. Seeking legal counsel is not required unless the school denies reasonable accommodations. The best intervention is to support the student in obtaining academic accommodations to improve their performance while continuing their treatment plan.
Q: A patient presents to the ED with upper respiratory symptoms. History includes
hypertension (controlled on lisinopril) and schizoaffective disorder (stable on clozapine). ED tests include chest X-ray, sputum culture, and CBC with differential, showing low white blood cell and neutrophil counts. The emergency physician contacts the NP for a psychiatric consult. The NP calculates absolute neutrophil count (ANC) as 1,110/μL. How should the NP manage this case?
a. Stop clozapine, monitor ANC daily for one month, and coordinate care with an outpatient psychiatric prescriber. b. Stop clozapine, monitor ANC three times weekly, and coordinate care with a hematologist. c. Continue clozapine, monitor ANC daily for one month, and coordinate care with a hematologist. d. Continue clozapine, monitor ANC three times weekly until it exceeds 1,500/μL, and coordinate care with an outpatient psychiatric prescriber. ANS: D The appropriate management is to continue clozapine (Clozaril), monitor ANC three times weekly until it is greater than 1,500/μL, and coordinate care with an outpatient psychiatric prescriber. The patient's absolute neutrophil count (ANC) is 1,110/μL, which falls into the moderate neutropenia range (ANC 1,000-1,499/μL) according to the Clozapine Risk Evaluation and Mitigation Strategy (REMS) guidelines. In cases of moderate neutropenia, clozapine can typically be continued with frequent ANC monitoring (three times weekly) until the neutrophil count recovers. Coordination with the psychiatric prescriber is essential to ensure continued treatment while balancing the risk of worsening neutropenia. Immediate discontinuation of clozapine is not necessary at this ANC level unless there is a further decline or clinical worsening. Hematology consultation is generally reserved for cases of severe neutropenia (ANC < 1,000/μL). Thus, the best approach is to continue clozapine, monitor ANC three times weekly, and coordinate care with outpatient psychiatry to ensure safe continuation of treatment.
Q: A 20-year-old patient arrives at a psychiatric crisis center with a friend. The patient is
exhibiting symptoms of mood lability, hallucinations, and paranoia. The nurse practitioner (NP) decides to prescribe a second-generation antipsychotic medication to target the acute psychotic symptoms and arranges for inpatient admission. Which baseline lab should this NP order and continue to monitor throughout the treatment? a. Urine drug screen b. Ferritin level c. Fasting lipids d. Urinalysis ANS: C
Q: A patient is stable with minimal side effects on olanzapine (Zyprexa) for symptoms of
schizophrenia. After consulting with the patient, a nurse practitioner (NP) student asks the preceptor about the dopamine theory. What should the preceptor provide as the premise of this theory? a. The N-methyl-D-aspartate receptor (NMDAR) hypofunction affects dopamine transmission. b. Hyperactivity of dopamine at D2 receptors is found in the mesolimbic pathway. c. Neurotransmitters serotonin, norepinephrine, or dopamine are depleted in the central nervous system. d. Hypoactive dopamine transmission stimulates the 5HT2A receptor hyperfunction in the cortex. ANS: B The dopamine theory of schizophrenia is based on the premise that hyperactivity of dopamine at D2 receptors in the mesolimbic pathway is associated with positive symptoms of schizophrenia, such as hallucinations, delusions, and thought disorder. This theory suggests that excess dopamine transmission in the mesolimbic pathway contributes to psychosis, while dopamine hypofunction in the mesocortical pathway may be responsible for negative symptoms and cognitive deficits. N-methyl-D-aspartate receptor (NMDAR) hypofunction (option A) is part of the glutamate hypothesis, which suggests that NMDAR dysfunction may contribute to schizophrenia. The depletion of serotonin, norepinephrine, or dopamine (option C) is more relevant to the monoamine hypothesis of depression, not schizophrenia. Hypoactive dopamine transmission stimulating 5HT2A receptor hyperfunction in the cortex (option D) is not the primary mechanism of schizophrenia, although serotonin modulation plays a role in atypical antipsychotic effects. Thus, the dopamine theory of schizophrenia is primarily centered on D2 receptor hyperactivity in the mesolimbic pathway, which explains positive symptoms and supports the mechanism of dopamine-blocking antipsychotics like olanzapine (Zyprexa). A nurse practitioner (NP) is discharging a patient on an antipsychotic medication from an inpatient setting. Which education should this NP include in the discharge teaching plan? a. Avoid excessive exposure to sunlight
b. Minimize physical activity c. Rinse mouth thoroughly d. Drink lots of water to avoid constipation ANS: A Patients taking antipsychotic medications should avoid excessive exposure to sunlight due to the risk of photosensitivity and heat intolerance. Many first- and second-generation antipsychotics can cause photosensitivity reactions, increasing the risk of sunburn and skin damage. Patients should be advised to wear sunscreen, protective clothing, and sunglasses when outdoors. Minimizing physical activity (option B) is not necessary unless the patient experiences sedation or orthostatic hypotension. Rinsing the mouth (option C) is more relevant for anticholinergic side effects or dry mouth, which can occur with some antipsychotics but is not a universal precaution. Drinking water to avoid constipation (option D) is helpful, but managing hydration is more important for preventing heat intolerance caused by these medications. Thus, the most important education for discharge teaching is to avoid excessive sun exposure and take precautions against photosensitivity and heat intolerance while taking antipsychotic medications. A patient is meeting with a nurse practitioner (NP) and has some questions about a new medication, aripiprazole (Abilify). The patient understands that aripiprazole is a second- generation antipsychotic. The patient wants to know what this drug blocks in the brain. Which response should this NP provide? a. Postsynaptic brain dopamine D2 receptors and serotonin receptors b. Reabsorption (reuptake) of serotonin into the neurons c. Reuptake of the neurotransmitters serotonin and norepinephrine d. Postsynaptic brain dopamine D2 receptors ANS: A Aripiprazole (Abilify) blocks postsynaptic dopamine D2 receptors and serotonin receptors while also acting as a partial agonist at dopamine D2 and serotonin 5-HT1A receptors. Unlike traditional antipsychotics, which primarily block dopamine, aripiprazole's unique mechanism helps balance dopaminergic activity, reducing both positive symptoms (hallucinations, delusions) and negative symptoms (apathy, social withdrawal) of schizophrenia. Reuptake inhibition of serotonin (option B) is the mechanism of selective serotonin reuptake inhibitors (SSRIs), such as fluoxetine (Prozac). Serotonin and norepinephrine reuptake inhibition (option C) describes the mechanism of serotonin-norepinephrine reuptake inhibitors
a. Hold the prescription and follow up with a primary care provider b. Hold the prescription and transfer the patient to an emergency department c. Refill the prescription, with a follow-up appointment in one month d. Refill the prescription and transfer the patient to a residential addiction program ANS: A The appropriate management is to hold the prescription and follow up with a primary care provider. The patient presents with acute signs of intoxication (alcohol odor, slurred speech, ataxia), raising concerns about substance misuse or potential interactions with stimulant medication. Stimulants, such as amphetamines and methylphenidate, can increase the risk of cardiovascular issues, mood instability, and further substance misuse when combined with alcohol or other substances. Transferring the patient to an emergency department (option B) is unnecessary unless they exhibit life-threatening symptoms, such as severe respiratory depression or altered mental status. Refilling the prescription (options C and D) is inappropriate in the setting of possible active substance use. While a referral to an addiction program may be warranted in the future, it should be based on a full assessment and patient readiness for treatment rather than an immediate decision. Thus, the best approach is to hold the stimulant prescription and arrange follow-up with a primary care provider to assess for substance use concerns and overall treatment appropriateness. A patient arrives at an emergency department unconscious with a respiratory rate of four breaths per minute and miotic pupils. Which treatment should be used for this patient? a. Albuterol (Ventolin) b. Naloxone (Narcan) c. Charcoal (Actidose) d. Lorazepam (Ativan) ANS: B Naloxone (Narcan) is the appropriate treatment for this patient, who presents with opioid overdose symptoms, including unconsciousness, respiratory depression (respiratory rate of four breaths per minute), and miotic (constricted) pupils. Naloxone is an opioid antagonist that rapidly reverses the effects of opioids, restoring normal breathing and consciousness. It should be administered immediately to prevent fatal respiratory failure.
Albuterol (Ventolin) is a bronchodilator used for asthma and bronchospasms but does not reverse opioid overdose. Activated charcoal (Actidose) is used for certain oral poisonings, but it is not effective for opioid overdose, particularly in an unconscious patient with respiratory depression. Lorazepam (Ativan) is a benzodiazepine, which could worsen sedation and respiratory depression in opioid toxicity. Thus, naloxone is the best choice for treating opioid overdose and should be given immediately to restore respiratory function. A patient presents with perioral dermatitis, unsteady gait, and tremor and has a strong odor of glue. The patient endorses huffing glue. Which physiological process explains these symptoms? a. Peripheral vasoconstriction b. Central nervous system depression c. Peripheral vasodilation d. Central nervous system stimulation ANS: B Central nervous system (CNS) depression explains this patient's symptoms. Inhalant abuse ("huffing glue") involves inhaling volatile substances, such as toluene, which act as CNS depressants by enhancing gamma-aminobutyric acid (GABA) activity and inhibiting glutamate. This results in drowsiness, slurred speech, ataxia (unsteady gait), and tremors. Chronic inhalant use can also lead to perioral dermatitis due to direct skin irritation from repeated exposure. Peripheral vasoconstriction (option A) is not a primary effect of inhalant use. Peripheral vasodilation (option C) may occur with some substances but is not the main physiological process causing these symptoms. CNS stimulation (option D) is associated with stimulants like cocaine and amphetamines, whereas inhalants primarily cause CNS depression. Thus, CNS depression is the primary physiological process responsible for the patient's symptoms. A 16-year-old patient is brought in by a family member after the patient ingested an unknown substance and the family member witnessed a seizure. Further assessment indicates hyperthermia, hyperreflexia, and signs of dehydration. The patient is admitted overnight for monitoring and to ensure all medical conditions are stabilized. Which substance causes these symptoms?
Duloxetine (Cymbalta) (option A) is an SNRI used for depression and anxiety but is not indicated for acute mania or treatment-resistant bipolar disorder. Lithium (Eskalith) (option B) is a first-line mood stabilizer for bipolar disorder, but since this patient is treatment-resistant, lithium alone may not be effective. Selegiline (Emsam) (option D) is an MAOI antidepressant used for treatment-resistant depression but has no role in acute mania or bipolar disorder treatment. Thus, clozapine is the best choice for off-label use in treatment-resistant bipolar disorder, particularly when other medications have failed. A nurse practitioner (NP) is assessing a 25-year-old patient who has a history of a traumatic brain injury (TBI). Collateral information obtained by the patient's parents includes periods of agitation and aggression. The parents are concerned that one of the patient's medications may be causing the agitation. Which medications may cause paradoxical agitation given this patient's history? a. Antipsychotics b. Benzodiazepines c. Beta blockers d. Sedatives ANS: B Benzodiazepines may cause paradoxical agitation in patients with a history of traumatic brain injury (TBI). While benzodiazepines are typically used for sedation, anxiety, and agitation, they can have the opposite effect in some individuals, particularly in those with TBI, elderly patients, or individuals with cognitive impairments. This reaction may present as increased agitation, aggression, impulsivity, and disinhibition, worsening the patient's symptoms instead of alleviating them. Antipsychotics (option A) may be used for agitation, but they do not typically cause paradoxical agitation; however, some can have sedative effects or exacerbate cognitive impairment. Beta blockers (option C) are sometimes used off-label to reduce aggression and agitation in TBI patients. Sedatives (option D) is a broad category that includes benzodiazepines, but other sedatives, such as certain antipsychotics or alpha-2 agonists, do not typically cause paradoxical agitation. Thus, benzodiazepines are the most likely culprit for paradoxical agitation in this patient with a history of TBI.
A nurse practitioner (NP) is evaluating a patient for shift work sleep disorder. The patient works from 11:00 p.m. to 7:00 a.m. five days per week and expresses having trouble staying asleep, feeling excessively fatigued, and often feeling restless. The patient denies previous history of these symptoms prior to starting the night shift. Which medication is FDA approved for this condition? a. Mirtazapine (Remeron) b. Trazodone (Desyrel) c. Modafinil (Provigil) d. Temazepam (Restoril) ANS: C Modafinil (Provigil) is FDA-approved for the treatment of shift work sleep disorder (SWSD). SWSD occurs in individuals who work nontraditional hours, such as night shifts, and experience excessive sleepiness during wake hours and difficulty sleeping during the day. Modafinil is a wake-promoting agent that helps improve alertness and reduce excessive daytime sleepiness without the addictive potential of traditional stimulants. Mirtazapine (Remeron) (option A) is an antidepressant with sedative properties, which may worsen sleep disturbances in SWSD rather than improve wakefulness. Trazodone (Desyrel) (option B) is commonly used for insomnia, but it is not FDA-approved for SWSD and may cause excessive sedation. Temazepam (Restoril) (option D) is a benzodiazepine hypnotic, which is used for insomnia but is not indicated for shift work sleep disorder. Thus, modafinil is the best choice for treating shift work sleep disorder to promote wakefulness and manage excessive fatigue. A patient with chronic nerve pain reports that they are experiencing restlessness, difficulty sleeping, ruminating thoughts, and constant worrying. Which drug should be prescribed to this patient to treat these symptoms? a. Gabapentin (Neurontin) b. Fluoxetine (Prozac) c. Venlafaxine (Effexor) d. Prazosin (Minipress) ANS: C Venlafaxine (Effexor) is the best choice for this patient, who presents with generalized anxiety disorder (GAD) symptoms alongside chronic nerve pain. Venlafaxine is a serotonin-
A nurse practitioner (NP) is interviewing a patient who complains of insomnia. The patient has used many FDA-approved medications to treat the condition. The patient has no history of substance abuse or any other issues with medication compliance. Which off-label medication should the NP prescribe for this patient? a. Venlafaxine (Effexor) b. Amitriptyline (Elavil) c. Fluoxetine (Prozac) d. Bupropion (Wellbutrin) ANS: B Amitriptyline (Elavil) is the best off-label medication choice for this patient with treatment- resistant insomnia. Amitriptyline is a tricyclic antidepressant (TCA) that has sedative properties due to its strong histamine (H1) receptor blockade, making it effective for sleep maintenance insomnia. It is often used at low doses for insomnia, chronic pain, and migraine prophylaxis. Venlafaxine (Effexor) (option A) is an SNRI that can actually cause insomnia as a side effect. Fluoxetine (Prozac) (option C) is an SSRI that is activating for many patients and may worsen insomnia. Bupropion (Wellbutrin) (option D) is a norepinephrine-dopamine reuptake inhibitor (NDRI) that is also stimulating and can contribute to sleep disturbances. Thus, amitriptyline is the best off-label choice for a patient with persistent insomnia who has not responded to FDA-approved treatments. A patient reports that they have had five years of heroin abuse but is currently sober. The patient was diagnosed with attention deficit hyperactivity disorder (ADHD) at 12 years of age and is currently struggling with focus and concentration. The patient was previously prescribed stimulant medications but prefers nonstimulants to support their sobriety. Which medication should be prescribed that has off-label use for this patient's condition? a. Amitriptyline (Elavil) b. Sertraline (Zoloft) c. Clonidine (Catapres) d. Prazosin (Minipress) ANS: C Clonidine (Catapres) is the best off-label medication choice for this patient with ADHD and a history of heroin abuse, who prefers nonstimulant treatment to support sobriety. Clonidine is an alpha-2 adrenergic agonist that helps regulate attention, reduce hyperactivity, and improve
impulse control by modulating norepinephrine activity in the prefrontal cortex. It is FDA- approved for pediatric ADHD but is also used off-label in adults who cannot tolerate or prefer to avoid stimulant medications. Amitriptyline (Elavil) (option A) is a tricyclic antidepressant used primarily for depression, insomnia, and chronic pain, but it is not a recognized treatment for ADHD. Sertraline (Zoloft) (option B) is an SSRI, effective for anxiety and depression but not for ADHD. Prazosin (Minipress) (option D) is an alpha-1 blocker used primarily for PTSD-related nightmares and hypertension, not ADHD. Thus, clonidine is the best choice for treating ADHD off-label in an adult patient with a history of substance use disorder, as it provides symptom relief without the risk of stimulant misuse. A patient is presently taking sertraline (Zoloft) for major depressive disorder with no reported benefit. The patient is reporting symptoms of fatigue that have not responded to the antidepressant. Which medication could be prescribed as an adjunct therapy for the fatigue based on current research? a. Mirtazapine (Remeron) b. Duloxetine (Cymbalta) c. Modafinil (Provigil) d. Atomoxetine (Strattera) ANS: C Modafinil (Provigil) is the best choice for adjunct therapy to address fatigue in a patient with major depressive disorder (MDD) who is not responding to sertraline (Zoloft). Modafinil is a wake-promoting agent that has been studied as an adjunct treatment for antidepressant- resistant fatigue and excessive daytime sleepiness in patients with depression. It works by modulating dopamine and norepinephrine activity, improving alertness and cognitive function without the addictive potential of traditional stimulants. Mirtazapine (Remeron) (option A) is sedating and would likely worsen fatigue. Duloxetine (Cymbalta) (option B) is an SNRI, which may help with energy and motivation, but it is another antidepressant rather than a targeted adjunct for fatigue. Atomoxetine (Strattera) (option D) is a non-stimulant ADHD medication that affects norepinephrine, but it is not commonly used to treat fatigue in depression. Thus, modafinil is the best adjunct therapy for persistent fatigue in MDD that has not responded to sertraline.
